Association Between Short-Term PASI90 Achievement and Drug Survival of Biologics in Patients with Psoriasis
- Author:
Sungjun CHOI
1
;
Sohee OH
;
Hyun-Sun YOON
Author Information
- Publication Type:Original Article
- From:Annals of Dermatology 2022;34(3):173-181
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:With accumulating evidence that achieving a 90% improvement in the Psoriasis Area and Severity Index score (PASI90) has better correlation with improved healthrelated quality of life as compared to PASI75 achievement, there has been demand for establishing new treatment goals for psoriasis.
Objective:We investigated whether the short-term PASI90 achievement would predict longer drug survival as compared to PASI75 achievement.
Methods:This single-center retrospective cohort study reviewed 180 treatment series in 128 patients with plaque psoriasis, who were treated with tumor necrosis factor-alpha inhibitors (n=12), ustekinumab (n=88), secukinumab (n=23), guselkumab (n=45), and ixekizumab (n=12). The first effectiveness assessment, usually performed within 12 to 20 weeks, was considered a short-term treatment response to biologics.
Results:After adjustment for covariates, time-dependent Cox proportional hazards regression analysis showed that moderate responders (short-term achievement of ≥PASI75 but
